Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...
Reports FY24 revenue $36.13M, consensus $37.63M. “We believe that petosemtamab’s receipt of two Breakthrough Therapy designations by the FDA – ...
The update was delivered at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February ...
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period.PD-L1 ...
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatment technologies have opened new avenues for ...
Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIR ...
Hosted on MSN21h
FDA grants fast track status to Pyxis’ PYX-201The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback